Credit Suisse Group restated their outperform rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research report released on Thursday. They currently have a $113.00 price target on the biotechnology company’s stock.

A number of other analysts have also recently commented on the stock. JPMorgan Chase & Co. set a $130.00 price target on shares of BioMarin Pharmaceutical and gave the company a buy rating in a research report on Sunday, October 29th. SunTrust Banks set a $115.00 price target on shares of BioMarin Pharmaceutical and gave the company a buy rating in a research report on Thursday, October 19th. Leerink Swann reaffirmed an outperform rating and set a $142.00 price target (up previously from $136.00) on shares of BioMarin Pharmaceutical in a research report on Thursday, October 19th. Jefferies Group reaffirmed a buy rating and set a $116.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, September 26th. Finally, Piper Jaffray Companies reaffirmed a buy rating and set a $113.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, September 21st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $111.69.

Shares of BioMarin Pharmaceutical (NASDAQ BMRN) traded down $0.66 during trading on Thursday, hitting $89.12. 939,067 shares of the company traded hands, compared to its average volume of 958,761. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical has a one year low of $80.10 and a one year high of $100.51. The company has a market capitalization of $15,651.34, a PE ratio of -99.02 and a beta of 1.82.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The company had revenue of $334.18 million for the quarter, compared to analysts’ expectations of $347.38 million. During the same quarter in the previous year, the firm posted $0.02 earnings per share. BioMarin Pharmaceutical’s revenue for the quarter was up 19.4% on a year-over-year basis. equities research analysts anticipate that BioMarin Pharmaceutical will post -0.64 EPS for the current year.

In other news, CEO Jean Jacques Bienaime sold 20,000 shares of the company’s stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $89.75, for a total transaction of $1,795,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Elaine J. Heron sold 800 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $88.90, for a total transaction of $71,120.00. Following the transaction, the director now owns 38,385 shares in the company, valued at approximately $3,412,426.50. The disclosure for this sale can be found here. Insiders have sold 60,750 shares of company stock worth $5,439,788 in the last quarter. Company insiders own 1.85% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in BMRN. Comerica Bank raised its holdings in shares of BioMarin Pharmaceutical by 1.0% during the second quarter. Comerica Bank now owns 7,358 shares of the biotechnology company’s stock valued at $662,000 after purchasing an additional 76 shares during the period. Cambridge Investment Research Advisors Inc. acquired a new position in shares of BioMarin Pharmaceutical during the second quarter valued at about $213,000. Alliancebernstein L.P. raised its holdings in shares of BioMarin Pharmaceutical by 2.4% during the second quarter. Alliancebernstein L.P. now owns 116,376 shares of the biotechnology company’s stock valued at $10,569,000 after purchasing an additional 2,756 shares during the period. Fiera Capital Corp raised its holdings in shares of BioMarin Pharmaceutical by 1.6% during the second quarter. Fiera Capital Corp now owns 6,613 shares of the biotechnology company’s stock valued at $601,000 after purchasing an additional 101 shares during the period. Finally, Amalgamated Bank raised its holdings in shares of BioMarin Pharmaceutical by 74.7% during the second quarter. Amalgamated Bank now owns 17,842 shares of the biotechnology company’s stock valued at $1,620,000 after purchasing an additional 7,628 shares during the period. Hedge funds and other institutional investors own 99.15% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/01/21/credit-suisse-group-reaffirms-outperform-rating-for-biomarin-pharmaceutical-bmrn.html.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.